

### **Amendments to the Claims**

#### **Listing of Claims:**

Original Claims 1-12 (canceled).

Amended Claims 1-16 (canceled).

Claim 17 (new). A buffered pharmaceutical preparation for nasal administration, the preparation comprising:

water;

at least one nasally administrable active pharmaceutical ingredient;

at least one preservative comprising benzalkonium chloride;

at least one buffer keeping the pH at 4 to 6, said at least one buffer comprising a malic acid compound; and

at least one agent selected from the group consisting of an osmotic agent and a wetting agent;

said preparation having substantially improved ciliary tolerability.

Claim 18 (new). The preparation according to claim 17, wherein said malic acid compound is present in a concentration in a range from 1 to 5 millimoles per liter of said pharmaceutical preparation.

Claim 19 (new). The preparation according to claim 17, wherein said buffer is formed with sodium as counter ion.

Claim 20 (new). The preparation according to claim 17, wherein said malic acid compound is selected from the group consisting of racemic malic acid and enantiopure malic acid.

Claim 21 (new). The preparation according to claim 17, wherein said osmotic agent comprises sodium chloride.

Claim 22 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is selected from the group consisting of at least one allergy remedy, at least one sympathomimetic remedy, at least one nasal catarrh remedy, at least one corticoid, at least one peptide, and at least one hormone.

Claim 23 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is selected from the group consisting of levocabastine, azelastine, cromoglicic acid, xylometazoline, tetrazoline, indanazoline, phenylephrine, naphazoline, tramazoline, oxymetazoline, beclometasone, triamcinolone, calcitonin, desmopressin, gonadorelin, buserelin, nafarelin, and oxytocin.

Claim 24 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is calcitonin.

Claim 25 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is cromoglycic acid.

Claim 26 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is desmopressin.

Claim 27 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is phenylephrine.

Claim 28 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is xylometazoline.

Claim 29 (new). The preparation according to claim 17, additionally comprising a buffer selected from the group consisting of a citrate buffer, a phosphate buffer, and an acetate buffer.

Claim 30 (new). The preparation according to claim 17, being an emulsion.

Claim 31 (new). The preparation according to claim 17, being a solution.

Claim 32 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is mucosally absorbable.

Claim 33 (new). The preparation according to claim 17, wherein said active pharmaceutical ingredient is locally effective.

Claim 34 (new). A method of treating a condition selected from the group consisting of allergy, bleeding disorder, diuretic impairment, and osteoporosis, comprising the intranasal administration to a person in need of such treatment of the preparation according to claim 17.

Claim 35 (new). The method of claim 34, which comprises treating the person by administering the preparation via a nasal spray.

Claim 36 (new).. The method of claim 34, which comprises treating the person by administering the preparation via nose drops.

Claim 37 (new). A method of preparing a buffered pharmaceutical preparation for nasal administration and having substantially improved ciliary tolerability, the method which comprises:

providing water;

admixing at least one nasally administrable active pharmaceutical ingredient;

admixing at least one preservative comprising benzalkonium chloride and at least one agent selected from the group consisting of an osmotic agent and a wetting agent; and

buffering the preparation to a pH of 4 to 6 with at least one buffer at least primarily comprising a malic acid compound.